<DOC>
	<DOCNO>NCT02436447</DOCNO>
	<brief_summary>This study Phase 1 , open-label , parallel group , multiple dose study , subject 18 year , evaluate safety , tolerability , pharmacokinetics one-hour intravenous infusion MTP-131 administer 7 consecutive day . Twenty-four subject plan enrol 4 cohort vary renal function , cohort consist 6 subject .</brief_summary>
	<brief_title>A Phase 1 Study Investigating Safety Pharmacokinetics Repeat-dose Intravenous Infusion MTP-131 Subjects With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subject ≥18 yearsofage Screening Visit . Subject sign ICF study specific procedure perform . Subjects select cohort must satisfy follow creatinine clearance ( CLCR ) criterion ( determine 24 hour urine collection analysis ) : Cohort 1 Normal Renal Function , 24 hour CLCR ≥ 90 mL/min Cohort 2 Mild renal impairment , 24 hour CLCR ≥ 6089 mL/min Cohort 3 Moderate renal impairment , 24 hour CLCR ≥ 3059 mL/min Cohort 4 Severe renal impairment , 24 hour CLCR &lt; 30 require dialysis Have history stable renal impairment determine standard estimate creatinine clearance methodology ( least 1 month within descriptive cohort ) stable physical condition base finding medical history . Women childbearing potential must agree use 1 follow method birth control date sign ICF two month last dose study drug : 1 . Abstinence , line prefer usual lifestyle subject . Subject agree use acceptable method contraception become sexually active . 2 . Maintenance monogamous relationship male partner surgically sterilize vasectomy ( vasectomy procedure must conduct least 60 day prior Screening Visit confirm via sperm analysis ) . 3 . Barrier method ( e.g. , condom occlusive cap ) spermicidal foam/gel/film/cream AND either hormonal contraception ( oral , implanted , injectable ) intrauterine device system . Subject history concurrent medical condition , opinion investigator , significantly increase potential risk associate administration MTP131 aspect study participation , exception renal impairment . Female subject pregnant , plan become pregnant , lactate . Subject history cancer ( exception nonmelanoma skin cancer ) , unless subject documentation complete curative treatment Subject history renal transplantation . Subject active inflammatory renal disease . Subject history histamine intolerance ( e.g. , known deficiency endogenous exogenous histamine degradation ) . Subject currently receive treatment chemotherapeutic agent immunosuppressant agent . Subject positive serology HIV 1 , HIV 2 , HBsAg HCV . Subject donate receive blood blood product within past 30 day . Subject participate clinical study involve investigational product within 30 day prior plan date study drug administration . Subject history clinically significant hypersensitivity allergy excipients contain study drug . Subject history active alcoholism drug addiction year Screening Visit . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Renal Impairment , Renal function , MTP-131 , Bendavia™</keyword>
</DOC>